Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Europe Alpha-Emitting Radioligand Therapy Market Trends and Forecast to 2035 | 26% CAGR Drives Market Toward USD 0.40 Billion as Isotope Capacity and Oncology Pipelines ExpandBoost ROI by securing isotope supply, scaling GMP manufacturing, forming CDMO partnerships and targeting PSMA-led prostate cancer opportunities.
- Everest Medicines Announces the Acceptance and Priority Review of VELSIPITY(R) Manufacturing Localization Application by the Center for Drug Evaluation of China's NMPA, Driving Continued Commercial MomentumHong Kong, Oct 2, 2026 - Everest Medicines recently announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted the application for localized manufacturing for VELSIPITY(R) (etrasimod arginine tablets) and granted Priority Review. Localized manufacturing of VELSIPITY(R) is expected to begin in 2027, further enhancing supply capacity and supply security in China and across the Asia-Pacific region. The acceptance marks progress in the Company’s planned commercialization of VELSIPITY(R). The VELSIPITY(R) localized production project has been progressing steadily since its launch at the Company’s global manufacturing facility in Jiashan in March 2025, with ongoing efforts focused on technology transfer, process optimization and preparations for localized manufacturing. Upon commencement of production, the facility is expected to have an annual production capacity of up to 50 million tablets, helping to strengthen supply stability, reduce manufacturing costs and improve operational efficiency, while supporting the commercialization of VELSIPITY(R). VELSIPITY(R) was approved by NMPA in February, 2026, for the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent. As a next-generation highly selective S1P receptor modulator, VELSIPITY(R) offers the potential for rapid onset of action, and long-lasting clinical remission and mucosal healing through an oral, once-daily regimen for adult patients with moderately to severely active UC. The first prescription of VELSIPITY(R) in China was issued in March 2026, making its entry into clinical use. Alongside its rapid commercialization, the Company is actively participating in negotiations for the inclusion of VELSIPITY(R) in the National Reimbursement Drug List (NRDL). VELSIPITY(R) has been approved in several territories licensed to Everest Medicines, including mainland China, Hong Kong SAR, Macao SAR, Singapore, and South Korea, and is expected to receive NDA approval in Taiwan, China in the second half of 2026. On the clinical front, Ulcerative colitis (UC) is a chronic, relapsing, non-specific inflammatory bowel disease. In China, the incidence and prevalence of UC continue to increase, with a clear trend toward younger patients. The patient population is projected to increase from approximately 0.98 million in 2025 to 1.50 million by 20311,2. Multiple studies of VELSIPITY(R) presented at the 21st Congress of the European Crohn’s and Colitis Organization (ECCO 2026) and the 14th Annual Meeting of the Asian Organization for Crohn’s and Colitis (AOCC 2026) further supported its clinical profile. The data demonstrated sustained efficacy with continuous treatment for up to 3 years3. Durable benefit was observed in patients who had received only 5-ASA/thiopurine treatment, and in biologic-experienced patients4,5. Benefit was also demonstrated in patients with mildly to moderately active UC6, with favorable long-term safety and tolerability maintained for up to 5 years of treatment7. These findings further strengthen the clinical evidence base of VELSIPITY(R). The clinical value of VELSIPITY(R) has been recognized in leading international clinical guidelines. Following its inclusion in the American Gastroenterological Association (AGA) Clinical Practice Guideline in December 2024 as a first-line treatment for ulcerative colitis, VELSIPITY(R) was also included in the 2025 American College of Gastroenterology (ACG) Clinical Guideline, the 2026 Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines and the 2026 European Crohn's and Colitis Organization (ECCO) Guidelines. Everest Medicines has a commercial-scale global manufacturing site in Jiashan, Zhejiang Province. It has established a complete GMP production quality management system complying with Chinese, EU and WHO standards and holds the manufacturing license. Localized manufacturing is expected to further enhance the commercial potential of VELSIPITY(R) by improving supply reliability and operational efficiency in China. Supported by Everest Medicines’ A2MS commercial operating system and lean management capabilities, the localized production of VELSIPITY(R) will strengthen the foundation for its continued expansion in China and further build the Company’s commercial capabilities in autoimmune diseases, supporting its long-term growth. Reference1. Shao B, et al. Front Public Health. 2022 Oct 25;10:1032679.2. Kaplan GG. Nat Rev Gastroenterol Hepatol. 2015;12(12):720-727.3. D T Rubin, et al. Journal of Crohn's and Colitis, 2026, jjaf231.774.4. B E Sands, et al. Journal of Crohn's and Colitis, 2026, jjaf231.1105.5. C Zheng, et al. Journal of Crohn's and Colitis, 2026, jjaf231.1046.6. D T Rubin, et al. Journal of Crohn's and Colitis, 2026, jjaf231.100.7. D T Rubin, et al. Journal of Crohn's and Colitis, 2026, jjaf231.1256.
- Everest Medicines Announces the Acceptance and Priority Review of VELSIPITY(R) Manufacturing Localization Application by the Center for Drug Evaluation of China's NMPA, Driving Continued Commercial MomentumHong Kong, Oct 2, 2026 - Everest Medicines recently announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted the application for localized manufacturing for VELSIPITY(R) (etrasimod arginine tablets) and granted Priority Review. Localized manufacturing of VELSIPITY(R) is expected to begin in 2027, further enhancing supply capacity and supply security in China and across the Asia-Pacific region. The acceptance marks progress in the Company’s planned commercialization of VELSIPITY(R). The VELSIPITY(R) localized production project has been progressing steadily since its launch at the Company’s global manufacturing facility in Jiashan in March 2025, with ongoing efforts focused on technology transfer, process optimization and preparations for localized manufacturing. Upon commencement of production, the facility is expected to have an annual production capacity of up to 50 million tablets, helping to strengthen supply stability, reduce manufacturing costs and improve operational efficiency, while supporting the commercialization of VELSIPITY(R). VELSIPITY(R) was approved by NMPA in February, 2026, for the treatment of adult patients with moderately to severely active UC who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent. As a next-generation highly selective S1P receptor modulator, VELSIPITY(R) offers the potential for rapid onset of action, and long-lasting clinical remission and mucosal healing through an oral, once-daily regimen for adult patients with moderately to severely active UC. The first prescription of VELSIPITY(R) in China was issued in March 2026, making its entry into clinical use. Alongside its rapid commercialization, the Company is actively participating in negotiations for the inclusion of VELSIPITY(R) in the National Reimbursement Drug List (NRDL). VELSIPITY(R) has been approved in several territories licensed to Everest Medicines, including mainland China, Hong Kong SAR, Macao SAR, Singapore, and South Korea, and is expected to receive NDA approval in Taiwan, China in the second half of 2026. On the clinical front, Ulcerative colitis (UC) is a chronic, relapsing, non-specific inflammatory bowel disease. In China, the incidence and prevalence of UC continue to increase, with a clear trend toward younger patients. The patient population is projected to increase from approximately 0.98 million in 2025 to 1.50 million by 20311,2. Multiple studies of VELSIPITY(R) presented at the 21st Congress of the European Crohn’s and Colitis Organization (ECCO 2026) and the 14th Annual Meeting of the Asian Organization for Crohn’s and Colitis (AOCC 2026) further supported its clinical profile. The data demonstrated sustained efficacy with continuous treatment for up to 3 years3. Durable benefit was observed in patients who had received only 5-ASA/thiopurine treatment, and in biologic-experienced patients4,5. Benefit was also demonstrated in patients with mildly to moderately active UC6, with favorable long-term safety and tolerability maintained for up to 5 years of treatment7. These findings further strengthen the clinical evidence base of VELSIPITY(R). The clinical value of VELSIPITY(R) has been recognized in leading international clinical guidelines. Following its inclusion in the American Gastroenterological Association (AGA) Clinical Practice Guideline in December 2024 as a first-line treatment for ulcerative colitis, VELSIPITY(R) was also included in the 2025 American College of Gastroenterology (ACG) Clinical Guideline, the 2026 Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines and the 2026 European Crohn's and Colitis Organization (ECCO) Guidelines. Everest Medicines has a commercial-scale global manufacturing site in Jiashan, Zhejiang Province. It has established a complete GMP production quality management system complying with Chinese, EU and WHO standards and holds the manufacturing license. Localized manufacturing is expected to further enhance the commercial potential of VELSIPITY(R) by improving supply reliability and operational efficiency in China. Supported by Everest Medicines’ A2MS commercial operating system and lean management capabilities, the localized production of VELSIPITY(R) will strengthen the foundation for its continued expansion in China and further build the Company’s commercial capabilities in autoimmune diseases, supporting its long-term growth. Reference 1. Shao B, et al. Front Public Health. 2022 Oct 25;10:1032679. 2. Kaplan GG. Nat Rev Gastroenterol Hepatol. 2015;12(12):720-727. 3. D T Rubin, et al. Journal of Crohn's and Colitis, 2026, jjaf231.774. 4. B E Sands, et al. Journal of Crohn's and Colitis, 2026, jjaf231.1105. 5. C Zheng, et al. Journal of Crohn's and Colitis, 2026, jjaf231.1046. 6. D T Rubin, et al. Journal of Crohn's and Colitis, 2026, jjaf231.100. 7. D T Rubin, et al. Journal of Crohn's and Colitis, 2026, jjaf231.1256.
- Kaplan Fox & Kilsheimer LLPKaplan Fox Reminds Honeywell Aerospace Inc. (HONA) Investors with Significant Losses to Seek a Leadership Role Before Deadline on November 23, 2026Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Honeywell Aerospace Inc. ("Honeywell Aerospace" or the "Company") (NASDAQ: HONA) on behalf of investors that purchased or otherwise acquired Honeywell Aerospace common stock between June 29, 2026 and September 1, 2026 (the "Class Period").CLICK HERE TO JOIN THE CASEIf you are an investor in Honeywell Aerospace and have suffered losses, you may CLICK...
- Nouryon brings U.S. solar project online at Morris, Illinois, facilityGlobal specialty chemicals leader Nouryon today announced it has started generating solar power at its manufacturing plant in Morris, Ill., the company’s first solar project in the U.S. Developed in partnership with local energy provider Convergent Energy and Power, the installation supplies electricity directly to the site, advancing the company’s plans to use more electricity from renewable and low-carbon sources across its global operations. Nouryon expects the system to generate about 3,400 megawatt-hours of electricity a year, enough to cover about 10% of the site’s electricity needs and avoid an estimated 1,152 metric tons of greenhouse gas emissions annually.
- GMP Labeling Inc.GMP Labeling Celebrates 40 Years of US Manufacturing for Regulated IndustriesAs pharmaceutical and biotechnology sectors navigate evolving global supply chain risks, GMP Labeling Inc. is utilizing Manufacturing Day 2026 to highlight its nearly 40-year history as a domestic manufacturer of critical compliance...
- New Zealand Construction Market Size, Trends, and Forecast by Sector to 2030 | 4.7% Annual Growth Unlocks Transport, Renewable Energy, and Industrial OpportunitiesIdentify high-potential opportunities, validate strategies, assess competitive risks and track key trends through granular sector and project pipeline analysis
- Cell and Gene Therapy Bio-Manufacturing Market Global Report 2026: Market to Surge to $21.46 Billion by 2030 as Thermo Fisher Scientific, Merck KGaA, Lonza and Samsung Biologics Accelerate AutomationCompanies: Thermo Fisher Scientific Inc.Merck KGaABoost ROI with scalable viral-vector platforms, automated single-use processing, digital quality control, and expanded CDMO capacity through partnerships and acquisitions.
- NVIDIAProductive, Durable, Fungible: How NVIDIA AI Factories Maximize Return on InvestmentCompanies: NvidiaAI factories are built by the megawatt, even by the gigawatt. Each megawatt factory costs roughly $60 million, and AI factory operators will only commit capital on that scale with a clear view of the return on investment. Three key things shape AI factory returns: Earning capacity: What the factory could earn in a year […]
- SpyGlass Pharma Acquires Advanced Vision Science, Inc. (AVS), Securing Scalable Commercial IOL Supply and Accelerating Lens Portfolio Expansion CapabilitySpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma” or “Company”) announced today the acquisition of all the outstanding shares of common stock of Advanced Vision Science, Inc. (AVS), an ophthalmic medical device company and manufacturer of intraocular lenses (IOLs) and lens materials, for approximately $13 million in cash. This acquisition secures scalable commercial IOL manufacturing capacity for SpyGlass Pharma. AVS was a wholly owned subsidiary of Santen Pharmaceutical Co., Ltd (Santen) and is the current supplier of SpyGlass Pharma’s IOL in its two Phase 3 registrational trials evaluating the BIM-IOL System.
- Global Industrial Centrifugal Compressor Market Strategic Analysis and Forecast, 2026-2031 | Hydrogen, CCUS, and Energy Storage Investments Fuel 3% to 5% CAGRMaximize ROI with energy-efficient upgrades, variable-speed drives, predictive maintenance and lifecycle services while targeting hydrogen, CCUS and energy storage demand.
- Global Industrial Process Centrifugal Compressor Market Size, Share, Trends, and Forecast 2026-2031 | LNG, Hydrogen, CCUS, and Electrification Unlock Growth OpportunitiesROI opportunities center on aftermarket services, compressor retrofits, predictive maintenance, electrification, and standardized systems that cut downtime, costs, and lead times.